‘Pure pharma’ companies were the minority a decade ago but are now back in fashion
Unit accounts for a fifth of group sales and could be spun off
Health service to target use of Novartis drug inclisiran in bid to prevent cardiovascular disease in England
Trial results for new targeted therapy ‘pretty remarkable’, says CEO
Swiss drugmaker?says backlog reflects stretched healthcare systems and patient reluctance to visit doctors for screenings
Rome’s talks with manufacturers come as EU seems to be moving away from AstraZeneca and J&J
The pharmaceuticals are battling in similar markets, but their share price performances have diverged
Pharmaceutical company legal teams had to act quickly on Covid-related problem-solving
German group’s treatment is among only 9 candidates to have entered a phase 3 trial
Pharma group was accused of paying bribes to doctors and improperly funding drug purchases
Pandemic shows purpose can defy sceptics. Plus: six general counsel who stand out on sustainability
Shortages of antimalarials and inhalers feared as purchases spike
The Novartis boss realised he had to radically change his traditional management ideas
Sandoz reaches $195m criminal settlement with US DoJ related to four conspiracies
Drugs that treat rare diseases can be good for wealth as well as health
Novel gene therapy a boon to Swiss drugmaker
Two $2m treatments launch this year but a reluctance to fork out could dim investor enthusiasm
Twice-yearly injection of cholesterol-lowering medicine aims to save thousands of lives
Pharma focus on rare diseases has curbed investment in tackling common conditions
Prospering Chinese and Indian citizens could constitute a lucrative market
Swiss company looks to restock pipeline with acquisition of The Medicines Company
Five-year agreement is one of the most expansive tie-ups between big pharma and big tech
Company faces possible civil or criminal charges over manipulated Zolgensma data
US regulator investigates timing of revelation about studies behind world’s most expensive drug
Swiss drugmaker expects its China sales to overtake Europe
